Shares in Quebec drug maker Labopharm Inc. surged as much as 13% in Wednesday trading after the company said it received approval for its twice-daily tramadol-acetaminophen product in eight European countries
CALGARY, Alberta, April 16, 2010 (GLOBE NEWSWIRE) -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Labopharm Inc. (Nasdaq:DDSS). Emerging Stock Report is currently offering a
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.